Shots:
- Amid rising R&D costs and tighter timelines, AI has evolved from a supporting tool to a central driver of biopharma deal-making, discovery strategies, and long-term value creation
- AI-led licensing deals, platform partnerships, and new valuation models are reshaping biotech–pharma collaborations, with platforms and proprietary datasets increasingly rivaling or surpassing traditional pipelines in deal value and structure
- Beyond transactions, this magazine highlights how AI is taking center stage in biopharma dealmaking and R&D, transforming discovery productivity while placing greater emphasis on proven impact, data integrity, and scalable execution as critical value drivers
[ps_download_button]
Get a chance to advertise with us! Send us your promotional pieces at connect@pharmashots.com
